48. 原発性抗リン脂質抗体症候群 Primary antiphospholipid syndrome Clinical trials / Disease details
臨床試験数 : 4 / 薬物数 : 5 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03540810 (ClinicalTrials.gov) | August 15, 2018 | 27/4/2018 | Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome | Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome | Primary Antiphospholipid Syndrome | Drug: Hydroxychloroquine;Drug: Placebo | University Hospital, Angers | NULL | Not yet recruiting | 18 Years | N/A | All | 300 | Phase 3 | France |
2 | NCT04153201 (ClinicalTrials.gov) | January 15, 2013 | 21/10/2019 | Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome | Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study. | Antiphospholipid Syndrome | Drug: Hydroxychloroquine | National and Kapodistrian University of Athens | NULL | Completed | 18 Years | N/A | All | 50 | N/A | Greece |